Seroprevalensstudie for kikhoste og andre vaksineforebyggbare sykdommer i Norge
We will carry out a seroepidemiological study in the Norwegian population to map the immune status against Bordetella pertussis in the population.
About the project
-
Project period: 21.02.2012 - 31.12.2026 (Active)
- Coordinating Institution: Norwegian Institute of Public Health
-
Project Manager:
- Audun Aase, Norwegian Institute of Public Health
-
Project Participants:
- Tove Karin Herstad, Method Development and Analytics
- Gro Tunheim, Method Development and Analytics
- Didrik Frimann Vestrheim, Infection Control and Vaccines
- Jann Storsæter, Infection Control and Vaccines
- Ida Laake, Method Development and Analytics
- Ingeborg Aase S. Aaberge, Infection Control
Summary
Reported pertussis incidence in Norway is the highest in Europe although the vaccination coverage is very high. We will carry out a seroepidemiological study in the Norwegian population to map the immune status against Bordetella pertussis in the population. Immunity against B. pertussis may be due to infection or vaccination, and by comparing immune status with vaccination status, this study can provide knowledge about both the vaccine effect and the occurrence of the pertussis in Norway. Statistical strength calculation shows that we should collect about 263 serum samples in each age group below 18 years and approximately 152 serum samples in each age group above 18 years, giving a total of 3010 samples. The results of the study will be of importance for our vaccine recommendation and for targeted prevention of pertussis. It may also be appropriate to investigate seroprevalence against other vaccine preventable diseases.